yahoo Press
Canaccord Says AbbVie’s (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook
Images
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational. AbbVie Inc. (NYSE:ABBV) is included among the Top 10 Blue Chip Stocks with Growing Dividends. On June 23, Canaccord raised its price recommendation on AbbVie Inc. (NYSE:ABBV) to $273 from $265. It reiterated a Buy rating on the shares. The firm updated its model following AbbVie's announced acquisition of Apogee Therapeutics (APGE). Canaccord said the deal makes strong strategic sense, as it adds a potential mega-blockbuster immunology asset targeting atopic dermatitis (AD) and asthma. The firm believes the asset could become a major growth driver for AbbVie over the next decade. On June 22, Wells Fargo maintained an Overweight rating on AbbVie. It also set a $260 price target on the stock. In a research note, the firm said AbbVie's reported bid for Apogee Therapeutics is logical because Apogee scores highly on its M&A screening framework. Wells Fargo told investors that such a transaction would likely be viewed positively by the market and could support AbbVie's shares. The firm also noted that the deal could create pressure on Regeneron by increasing competition in the space. AbbVie Inc. (NYSE:ABBV) is a global, diversified, research-based biopharmaceutical company. The company focuses on the research and development, manufacturing, commercialization, and sale of medicines and therapies. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 11 Dividend Kings to Buy for Safe Dividend Growth and Billionaire Mario Gabelli's Top 12 Dividend Stocks Disclosure: None. Follow Insider Monkey on Google News.
Comments
You must be logged in to comment.